Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Nigro

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Hand Clinics|March 31, 2001
Anatomy of the flexor retinaculum of the wrist and the flexor carpi radialis tunnelR O Nigro
Internal Medicine Journal|March 20, 2004
Seroquel, Serzone and seizuresD L Worthley, N Burgess, O Nigro, et al.
Archives of Virology|January 28, 2004
Sequencing and characterization of the full-length gene encoding the single-stranded DNA binding protein of a novel Chelonian herpesvirusO Nigro, G Yu, A Alonso Aguirre, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|June 5, 2025
Assessment of Clinical and Neurological Alterations Before Radiation Therapy in Children With Malignant Brain TumoursM Lecchi, A Erbetta, P Grampa, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 9, 2019
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudesA Cortellini, A Leonetti, A Catino, et al.
ESMO Open|June 19, 2021
Corrigendum to 'The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer': [ESMO Open Volume 6, Issue 2, April 2021, 100078]G L Banna, A Cortellini, D L Cortinovis, et al.
ESMO Open|March 18, 2021
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancerG L Banna, A Cortellini, D L Cortinovis, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Hand Clinics|March 31, 2001
Anatomy of the flexor retinaculum of the wrist and the flexor carpi radialis tunnelR O Nigro
Internal Medicine Journal|March 20, 2004
Seroquel, Serzone and seizuresD L Worthley, N Burgess, O Nigro, et al.
Archives of Virology|January 28, 2004
Sequencing and characterization of the full-length gene encoding the single-stranded DNA binding protein of a novel Chelonian herpesvirusO Nigro, G Yu, A Alonso Aguirre, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|June 5, 2025
Assessment of Clinical and Neurological Alterations Before Radiation Therapy in Children With Malignant Brain TumoursM Lecchi, A Erbetta, P Grampa, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 9, 2019
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudesA Cortellini, A Leonetti, A Catino, et al.
ESMO Open|June 19, 2021
Corrigendum to 'The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer': [ESMO Open Volume 6, Issue 2, April 2021, 100078]G L Banna, A Cortellini, D L Cortinovis, et al.
ESMO Open|March 18, 2021
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancerG L Banna, A Cortellini, D L Cortinovis, et al.
Pageof 1